HIV-related cardiovascular disease, statins, and the REPRIEVE trial

Topics in Antiviral Medicine

Volumn 23, Issue 4, 2015, Pages 146-149

  Gilbert, Jennifer M ^a   Fitch, Kathleen V ^a   Grinspoon, Steven K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; CVD; HIV; REPRIEVE trial

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CYTOCHROME P450 3A; GLUCOSE; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; QUINOLINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; LIFESTYLE MODIFICATION; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION; SMOKING HABIT; TREATMENT OUTCOME; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; CONTROLLED STUDY; DRUG INTERACTION; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; UNITED STATES;

ADULT; AGED; ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; QUINOLINES; TREATMENT OUTCOME; UNITED STATES;

EID: 84949491521     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
2. Mitka M. Exploring statins to decrease HIV-related heart disease risk. JAMA. 2015;314(7):657-659.
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8): 614-622.
4. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243-253.
5. Zanni MV, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013;27(8):1263-1272.
6. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308(4):379-386.
7. Zanni MV, Fitch KV, Feldpausch M, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014; 28(14):2061-2070.
8. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22): 2283-2296.
9. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807.
10. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-1681.
11. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
12. Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150(5):301-313.
13. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV- infected subjects on antiretroviral therapy. JAIDS. 2015;68(4): 396-404.
14. Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52-e63.
15. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: AIDS Clinical Trials Group (ACTG) study A5047. AIDS. 2002;16:569-577.
16. Aberg JA, Sponseller CA, Kryzhanovski VA, Kartman CE, Thompson MA. Neutral effects of pitavastatin 4 mg and pravastatin 40 mg on blood glucose and HbA1c levels over 12 weeks: prespecified safety analysis from INTREPID (HIV-Infected Patients and Treatment With Pitavastatin vs Pravastatin for Dyslipidemia), a phase 4 trial. The Endocrine Society's 95th Annual Meeting and Expo. June 15-18, 2013; San Francisco, California.
17. Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. JAIDS. 2014;67(4):390-396.
18. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.